4.7 Review

HDL in sepsis - risk factor and therapeutic approach

期刊

FRONTIERS IN PHARMACOLOGY
卷 6, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2015.00244

关键词

high-density lipoprotein (HDL); apolipoprotein A-1 (Apokl); sepsis; lipopolysaccharide (LPS); sepsis therapy

资金

  1. R01GM113832 [NIGMS/NIH]
  2. ALIA [13SDG17230049]
  3. NTH [T32 GM008353]

向作者/读者索取更多资源

High density lipoprotein (HDL) is a key component of circulating blood and plays essential roles in regulation of vascular endothelial function and immunity. Clinical data demonstrate that HDL levels drop by 40-70% in septic patients, which is associated with a poor prognosis. Experimental studies using Apolipoprotein A-I (ApoAl) null mice showed that HDL deficient mice are susceptible to septic death, and overexpressing ApoAl in mice to increase HDL levels protects against septic death. These clinical and animal studies support our hypothesis that a decrease in HDL level is a risk factor for sepsis, and raising circulating HDL levels may provide an efficient therapy for sepsis. In this review, we discuss the roles of HDL in sepsis and summarize the efforts of using synthetic HDL as a potential therapy for sepsis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据